Asymptomatic Leishmania infection: a new challenge for Leishmania control.

Association of the Endobiont Double-Stranded RNA Virus LRV1 With Treatment Failure for Human Leishmaniasis Caused by Leishmania braziliensis in Peru and Bolivia. J Infect Dis (2015) 0.95

Understanding the transmission dynamics of Leishmania donovani to provide robust evidence for interventions to eliminate visceral leishmaniasis in Bihar, India. Parasit Vectors (2016) 0.90

Current challenges in treatment options for visceral leishmaniasis in India: a public health perspective. Infect Dis Poverty (2016) 0.84

A screen-and-treat strategy targeting visceral leishmaniasis in HIV-infected individuals in endemic East African countries: the way forward? PLoS Negl Trop Dis (2014) 0.84

Parasitological Confirmation and Analysis of Leishmania Diversity in Asymptomatic and Subclinical Infection following Resolution of Cutaneous Leishmaniasis. PLoS Negl Trop Dis (2015) 0.80

Cutaneous Infection with Leishmania major Mediates Heterologous Protection against Visceral Infection with Leishmania infantum. J Immunol (2015) 0.80

Cytokine Release Assays as Tests for Exposure to Leishmania, and for Confirming Cure from Leishmaniasis, in Solid Organ Transplant Recipients. PLoS Negl Trop Dis (2015) 0.79

Tilting the balance between RNA interference and replication eradicates Leishmania RNA virus 1 and mitigates the inflammatory response. Proc Natl Acad Sci U S A (2016) 0.79

Xenodiagnosis of Leishmania donovani in BALB/c mice using Phlebotomus orientalis: a new laboratory model. Parasit Vectors (2015) 0.78

Elimination of visceral leishmaniasis on the Indian subcontinent. Lancet Infect Dis (2016) 0.78

Developments in Diagnosis of Visceral Leishmaniasis in the Elimination Era. J Parasitol Res (2015) 0.77

Leishmaniasis revisited: Current aspects on epidemiology, diagnosis and treatment. J Transl Int Med (2015) 0.76

Elimination of Kala-Azar from the Southeast Asia Region. Am J Trop Med Hyg (2017) 0.75

Antiviral screening identifies adenosine analogs targeting the endogenous dsRNA Leishmania RNA virus 1 (LRV1) pathogenicity factor. Proc Natl Acad Sci U S A (2017) 0.75

Gene deleted live attenuated Leishmania vaccine candidates against visceral leishmaniasis elicit pro-inflammatory cytokines response in human PBMCs. Sci Rep (2016) 0.75

Continual renewal and replication of persistent Leishmania major parasites in concomitantly immune hosts. Proc Natl Acad Sci U S A (2017) 0.75

Asymptomatic leishmaniasis in kala-azar endemic areas of Malda district, West Bengal, India. PLoS Negl Trop Dis (2017) 0.75

Longitudinal Study of Transmission in Households with Visceral Leishmaniasis, Asymptomatic Infections and PKDL in Highly Endemic Villages in Bihar, India. PLoS Negl Trop Dis (2016) 0.75

Minimally invasive microbiopsies: a novel sampling method for identifying asymptomatic, potentially infectious carriers of Leishmania donovani. Int J Parasitol (2017) 0.75

Tropical Diseases on Insurgence: Clinician's Perspective. Indian J Dermatol (2017) 0.75

Leishmaniasis worldwide and global estimates of its incidence. PLoS One (2012) 18.07

Laboratory diagnosis of visceral leishmaniasis. Clin Diagn Lab Immunol (2002) 3.21

New perspectives on a subclinical form of visceral leishmaniasis. J Infect Dis (1986) 2.92

Risk factors for kala-azar in Bangladesh. Emerg Infect Dis (2005) 2.73

Endemic kala-azar in eastern Sudan: a longitudinal study on the incidence of clinical and subclinical infection and post-kala-azar dermal leishmaniasis. Am J Trop Med Hyg (1994) 2.45

The poorest of the poor: a poverty appraisal of households affected by visceral leishmaniasis in Bihar, India. Trop Med Int Health (2009) 2.35

Longlasting insecticidal nets for prevention of Leishmania donovani infection in India and Nepal: paired cluster randomised trial. BMJ (2010) 2.30

Factors associated with visceral leishmaniasis in Nepal: bed-net use is strongly protective. Am J Trop Med Hyg (2001) 2.09

Epidemiology of visceral leishmaniasis in northeast Brazil. J Infect Dis (1992) 1.99

Virgin soil: the spread of visceral leishmaniasis into Uttar Pradesh, India. Am J Trop Med Hyg (2005) 1.96

Diagnosis of visceral leishmaniasis. Trans R Soc Trop Med Hyg (2010) 1.93

Immunologic markers of clinical evolution in children recently infected with Leishmania donovani chagasi. J Infect Dis (1992) 1.90

Western blot analysis of antibodies to Leishmania infantum antigens: potential of the 14-kD and 16-kD antigens for diagnosis and epidemiologic purposes. Am J Trop Med Hyg (1992) 1.78

Serological diagnosis of Indian visceral leishmaniasis: direct agglutination test versus rK39 strip test. Trans R Soc Trop Med Hyg (2005) 1.75

Incidence of symptomatic and asymptomatic Leishmania donovani infections in high-endemic foci in India and Nepal: a prospective study. PLoS Negl Trop Dis (2011) 1.67

Risk factors for Indian kala-azar. Am J Trop Med Hyg (2005) 1.67

Visceral leishmaniasis in the Indian subcontinent: modelling epidemiology and control. PLoS Negl Trop Dis (2011) 1.64

The epidemiology of visceral leishmaniasis and asymptomatic leishmanial infection in a highly endemic Bangladeshi village. Am J Trop Med Hyg (2007) 1.55

IL-17 and IL-22 are associated with protection against human kala azar caused by Leishmania donovani. J Clin Invest (2009) 1.53

Malnutrition alters the innate immune response and increases early visceralization following Leishmania donovani infection. Infect Immun (2001) 1.37

SLC11A1 (formerly NRAMP1) and susceptibility to visceral leishmaniasis in The Sudan. Eur J Hum Genet (2004) 1.35

The interplay between environmental and host factors during an outbreak of visceral leishmaniasis in eastern Sudan. Microbes Infect (2002) 1.34

Longitudinal seroepidemiologic study of visceral leishmaniasis in hyperendemic regions of Bihar, India. Am J Trop Med Hyg (2009) 1.34

Asymptomatic infection with visceral leishmaniasis in a disease-endemic area in bihar, India. Am J Trop Med Hyg (2010) 1.34

Malnutrition as a risk factor for severe visceral leishmaniasis. J Infect Dis (1987) 1.32

Measurement of recent exposure to Phlebotomus argentipes, the vector of Indian visceral Leishmaniasis, by using human antibody responses to sand fly saliva. Am J Trop Med Hyg (2010) 1.30

Leishmania DNA is rapidly degraded following parasite death: an analysis by microscopy and real-time PCR. Microbes Infect (2007) 1.26

Interactions of malnutrition and immune impairment, with specific reference to immunity against parasites. Parasite Immunol (2006) 1.24

Visceral leishmaniasis in Ethiopia. IV. Prevalence, incidence and relation of infection to disease in an endemic area. Ann Trop Med Parasitol (1994) 1.23

Evaluation of leishmanin skin test in Indian visceral leishmaniasis. Am J Trop Med Hyg (2009) 1.22

Genetics and visceral leishmaniasis: of mice and man. Parasite Immunol (2009) 1.21

Reassessment of immune correlates in human visceral leishmaniasis as defined by cytokine release in whole blood. Clin Vaccine Immunol (2012) 1.20

Distinct innate and acquired immune responses to Leishmania in putative susceptible and resistant human populations endemically exposed to L. (Viannia) panamensis infection. Scand J Immunol (2000) 1.19

Latent infection with Leishmania donovani in highly endemic villages in Bihar, India. PLoS Negl Trop Dis (2013) 1.16

PCR and direct agglutination as Leishmania infection markers among healthy Nepalese subjects living in areas endemic for Kala-Azar. Trop Med Int Health (2009) 1.16

Common variants in the HLA-DRB1-HLA-DQA1 HLA class II region are associated with susceptibility to visceral leishmaniasis. Nat Genet (2013) 1.15

Risk factors for visceral leishmaniasis in India: further evidence on the role of domestic animals. Trop Med Int Health (2010) 1.10

Indirect xenodiagnosis of visceral leishmaniasis in 10 HIV-infected patients using colonized Phlebotomus perniciosus. AIDS (1994) 1.09

A leishmanin skin test survey in the human population of l'Alacantí region (Spain): implications for the epidemiology of Leishmania infantum infection in southern Europe. Trans R Soc Trop Med Hyg (2002) 1.07

Genetic control of visceral leishmaniasis in a Sudanese population: candidate gene testing indicates a linkage to the NRAMP1 region. Genes Immun (2003) 1.07

A prospective sero-epidemiological study of visceral leishmaniasis in Baringo District, Rift Valley Province, Kenya. Trans R Soc Trop Med Hyg (1996) 1.06

Strong association between serological status and probability of progression to clinical visceral leishmaniasis in prospective cohort studies in India and Nepal. PLoS Negl Trop Dis (2014) 1.06

T cell subset and cytokine profiles in human visceral leishmaniasis during active and asymptomatic or sub-clinical infection with Leishmania donovani. Clin Immunol (2005) 1.02

The murine model of infection with Leishmania major and its importance for the deciphering of mechanisms underlying differences in Th cell differentiation in mice from different genetic backgrounds. Int J Parasitol (2004) 1.02

Control of Leishmania infantum infection is associated with CD8(+) and gamma interferon- and interleukin-5-producing CD4(+) antigen-specific T cells. Infect Immun (1999) 0.99

Reducing visceral leishmaniasis by insecticide impregnation of bed-nets, Bangladesh. Emerg Infect Dis (2013) 0.97

Molecular and serological markers of Leishmania donovani infection in healthy individuals from endemic areas of Bihar, India. Trop Med Int Health (2013) 0.97

Visceral leishmaniasis in rural bihar, India. Emerg Infect Dis (2012) 0.96

Permissiveness of human monocytes and monocyte-derived macrophages to infection by promastigotes of Leishmania (Viannia) panamensis. J Parasitol (1998) 0.96

Factors associated with Leishmania asymptomatic infection: results from a cross-sectional survey in highland northern Ethiopia. PLoS Negl Trop Dis (2012) 0.94

Inaccuracy of enzyme-linked immunosorbent assay using soluble and recombinant antigens to detect asymptomatic infection by Leishmania infantum. PLoS Negl Trop Dis (2009) 0.93

Reciprocal relationships between undernutrition and the parasitic disease visceral leishmaniasis. Rev Infect Dis (1986) 0.92

Cytokine responses to novel antigens in an Indian population living in an area endemic for visceral leishmaniasis. PLoS Negl Trop Dis (2012) 0.90

Protein-energy malnutrition decreases immune response to Leishmania chagasi vaccine in BALB/c mice. Parasite Immunol (2009) 0.90

Human monocyte infection by Leishmania (Viannia) panamensis. Role of complement receptors and correlation of susceptibility in vitro with clinical phenotype. J Immunol (1994) 0.87

No evidence for association between SLC11A1 and visceral leishmaniasis in India. BMC Med Genet (2011) 0.86

Epidemiological study of risk factors related to childhood visceral leishmaniasis. Mymensingh Med J (2008) 0.85

Whole blood assay and visceral leishmaniasis: Challenges and promises. Immunobiology (2014) 0.82

The infection risk of visceral leishmaniasis among household members of active patients. Parasitol Int (2006) 0.80

Factors associated with asymptomatic infection in family members and neighbors of patients with visceral leishmaniasis. Cad Saude Publica (2012) 0.78

Asymptomatic carriage of Leishmania in family members of patients with visceral leishmaniasis in Central Tunisia. Pathol Biol (Paris) (2011) 0.77

ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation (2006) 13.21

Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke. Stroke (2003) 7.75

Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev Microbiol (2007) 7.36

Drug resistance in leishmaniasis. Clin Microbiol Rev (2006) 7.35

Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect Dis (2002) 7.17

ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. J Am Coll Cardiol (2006) 5.70

In vivo imaging reveals an essential role for neutrophils in leishmaniasis transmitted by sand flies. Science (2008) 5.09

CD4(+)CD25(-)Foxp3(-) Th1 cells are the source of IL-10-mediated immune suppression in chronic cutaneous leishmaniasis. J Exp Med (2007) 4.66

Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance. Clin Infect Dis (2013) 4.03

Phagosomes are competent organelles for antigen cross-presentation. Nature (2003) 3.97

ACC/AHA Guidelines for the Management of Patients with Peripheral Arterial Disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Associations for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (writing committee to develop guidelines for the management of patients with peripheral arterial disease)--summary of recommendations. J Vasc Interv Radiol (2006) 3.59

A meta-analysis of the diagnostic performance of the direct agglutination test and rK39 dipstick for visceral leishmaniasis. BMJ (2006) 3.11

Splenic accumulation of IL-10 mRNA in T cells distinct from CD4+CD25+ (Foxp3) regulatory T cells in human visceral leishmaniasis. J Exp Med (2007) 2.75

Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis. J Infect Dis (2007) 2.74

Unique gene expression profiles of human macrophages and dendritic cells to phylogenetically distinct parasites. Blood (2003) 2.65

Role for CD4(+) CD25(+) regulatory T cells in reactivation of persistent leishmaniasis and control of concomitant immunity. J Exp Med (2004) 2.57

Visceral leishmaniasis elimination programme in India, Bangladesh, and Nepal: reshaping the case finding/case management strategy. PLoS Negl Trop Dis (2009) 2.56

Control of visceral leishmaniasis in latin america-a systematic review. PLoS Negl Trop Dis (2010) 2.50

Guidelines for the use of retrievable and convertible vena cava filters: report from the Society of Interventional Radiology multidisciplinary consensus conference. J Vasc Interv Radiol (2006) 2.32

Leishmaniasis: new approaches to disease control. BMJ (2003) 2.30

Longlasting insecticidal nets for prevention of Leishmania donovani infection in India and Nepal: paired cluster randomised trial. BMJ (2010) 2.30

Image-guided tumor ablation: standardization of terminology and reporting criteria. J Vasc Interv Radiol (2009) 2.29

Determinants of survival in AIDS patients on antiretroviral therapy in a rural centre in the Far-North Province, Cameroon. Trop Med Int Health (2008) 2.28

Spread of vector-borne diseases and neglect of Leishmaniasis, Europe. Emerg Infect Dis (2008) 2.24

Interleukin-10 and the pathogenesis of human visceral leishmaniasis. Trends Immunol (2007) 2.23

Society of Interventional Radiology position statement on chemoembolization of hepatic malignancies. J Vasc Interv Radiol (2006) 2.22

Whole genome sequencing of multiple Leishmania donovani clinical isolates provides insights into population structure and mechanisms of drug resistance. Genome Res (2011) 2.21

Visceral leishmaniasis: elimination with existing interventions. Lancet Infect Dis (2011) 2.19

Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin Infect Dis (2006) 2.17

CD8+ T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge with Leishmania major. J Immunol (2002) 2.16

High incidence of zidovudine induced anaemia in HIV infected patients in eastern India. Indian J Med Res (2010) 2.11

Recurrence in tuberculosis: relapse or reinfection? Lancet Infect Dis (2003) 2.11

Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004. Lancet Infect Dis (2005) 2.06

The American "board" of vascular medicine: questions and concerns. J Vasc Interv Radiol (2005) 2.02

Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use. Clin Infect Dis (2012) 2.00

Quantification of the infectious dose of Leishmania major transmitted to the skin by single sand flies. Proc Natl Acad Sci U S A (2008) 1.98

Virgin soil: the spread of visceral leishmaniasis into Uttar Pradesh, India. Am J Trop Med Hyg (2005) 1.96

Combination therapy for visceral leishmaniasis. Lancet Infect Dis (2010) 1.96

Diagnosis of visceral leishmaniasis. Trans R Soc Trop Med Hyg (2010) 1.93

Integrating tuberculosis and HIV care in the primary care setting in South Africa. Trop Med Int Health (2004) 1.89

The effectiveness of active population screening and treatment for sleeping sickness control in the Democratic Republic of Congo. Trop Med Int Health (2004) 1.89

Training, competency, and credentialing standards for diagnostic cervicocerebral angiography, carotid stenting, and cerebrovascular intervention: a joint statement from the American Academy of Neurology, the American Association of Neurological Surgeons, the American Society of Interventional and Therapeutic Neuroradiology, the American Society of Neuroradiology, the Congress of Neurological Surgeons, the AANS/CNS Cerebrovascular Section, and the Society of Interventional Radiology. Neurology (2005) 1.88

Rapid diagnostic tests for neurological infections in central Africa. Lancet Infect Dis (2013) 1.82

Chemical and environmental vector control as a contribution to the elimination of visceral leishmaniasis on the Indian subcontinent: cluster randomized controlled trials in Bangladesh, India and Nepal. BMC Med (2009) 1.79

Drug uptake and modulation of drug resistance in Leishmania by an aquaglyceroporin. J Biol Chem (2004) 1.79

Guidelines for the reporting of renal artery revascularization in clinical trials. J Vasc Interv Radiol (2002) 1.75

Effectiveness and feasibility of active and passive case detection in the visceral leishmaniasis elimination initiative in India, Bangladesh, and Nepal. Am J Trop Med Hyg (2010) 1.74

Clinical and parasite species risk factors for pentavalent antimonial treatment failure in cutaneous leishmaniasis in Peru. Clin Infect Dis (2008) 1.73

Incidence of symptomatic and asymptomatic Leishmania donovani infections in high-endemic foci in India and Nepal: a prospective study. PLoS Negl Trop Dis (2011) 1.67

Diagnostic accuracy of two rK39 antigen-based dipsticks and the formol gel test for rapid diagnosis of visceral leishmaniasis in northeastern Uganda. J Clin Microbiol (2005) 1.67

Genetic characterization of glucose transporter function in Leishmania mexicana. Proc Natl Acad Sci U S A (2003) 1.64

Visceral leishmaniasis in the Indian subcontinent: modelling epidemiology and control. PLoS Negl Trop Dis (2011) 1.64

Vector control by insecticide-treated nets in the fight against visceral leishmaniasis in the Indian subcontinent, what is the evidence? Trop Med Int Health (2008) 1.63

Effect of village-wide use of long-lasting insecticidal nets on visceral Leishmaniasis vectors in India and Nepal: a cluster randomized trial. PLoS Negl Trop Dis (2010) 1.61

Immune privilege in sites of chronic infection: Leishmania and regulatory T cells. Immunol Rev (2006) 1.61

Implementation research to support the initiative on the elimination of kala azar from Bangladesh, India and Nepal--the challenges for diagnosis and treatment. Trop Med Int Health (2008) 1.59

A global comparative evaluation of commercial immunochromatographic rapid diagnostic tests for visceral leishmaniasis. Clin Infect Dis (2012) 1.59

Trypanosomiasis control, Democratic Republic of Congo, 1993-2003. Emerg Infect Dis (2005) 1.58

Mechanisms of experimental resistance of Leishmania to miltefosine: Implications for clinical use. Drug Resist Updat (2006) 1.58

Leishmania disease development depends on the presence of apoptotic promastigotes in the virulent inoculum. Proc Natl Acad Sci U S A (2006) 1.58

Endocrine changes in male HIV patients. J Assoc Physicians India (2011) 1.56

Multidisciplinary practical guidelines for gastrointestinal access for enteral nutrition and decompression from the Society of Interventional Radiology and American Gastroenterological Association (AGA) Institute, with endorsement by Canadian Interventional Radiological Association (CIRA) and Cardiovascular and Interventional Radiological Society of Europe (CIRSE). J Vasc Interv Radiol (2011) 1.55

Present situation of vector-control management in Bangladesh: a wake up call. Health Policy (2008) 1.54

How to shorten patient follow-up after treatment for Trypanosoma brucei gambiense sleeping sickness. J Infect Dis (2010) 1.53

Drug resistance in leishmaniasis. J Glob Infect Dis (2010) 1.52

Long-lasting insecticidal nets fail at household level to reduce abundance of sandfly vector Phlebotomus argentipes in treated houses in Bihar (India). Trop Med Int Health (2008) 1.51

Leishmaniases in the Mediterranean in the era of molecular epidemiology. Trends Parasitol (2008) 1.50

Insecticide susceptibility of Phlebotomus argentipes in visceral leishmaniasis endemic districts in India and Nepal. PLoS Negl Trop Dis (2010) 1.50

Molecular mechanisms of antimony resistance in Leishmania. J Med Microbiol (2007) 1.50

Multilocus microsatellite typing (MLMT) reveals genetic homogeneity of Leishmania donovani strains in the Indian subcontinent. Infect Genet Evol (2008) 1.49

Serial quantitative PCR assay for detection, species discrimination, and quantification of Leishmania spp. in human samples. J Clin Microbiol (2011) 1.48

Response to treatment in a prospective cohort of patients with large ulcerated lesions suspected to be Buruli Ulcer (Mycobacterium ulcerans disease). PLoS Negl Trop Dis (2010) 1.48

Quality improvement guidelines for uterine artery embolization for symptomatic leiomyomata. Cardiovasc Intervent Radiol (2004) 1.48

Quality improvement guidelines for percutaneous transhepatic cholangiography and biliary drainage. J Vasc Interv Radiol (2003) 1.48

Identification of genetic markers in sodium antimony gluconate (SAG) sensitive and resistant Indian clinical isolates of Leishmania donovani through amplified fragment length polymorphism (AFLP). Acta Trop (2009) 1.47

Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India. Clin Infect Dis (2003) 1.46

IL-27 regulates IL-10 and IL-17 from CD4+ cells in nonhealing Leishmania major infection. J Immunol (2009) 1.46

IL-27 and IL-21 are associated with T cell IL-10 responses in human visceral leishmaniasis. J Immunol (2011) 1.44

Visceral leishmaniasis in southeastern Nepal: a cross-sectional survey on Leishmania donovani infection and its risk factors. Trop Med Int Health (2006) 1.43

Training guidelines for intra-arterial catheter-directed treatment of acute ischemic stroke: a statement from a special writing group of the Society of Interventional Radiology. J Vasc Interv Radiol (2009) 1.42

Options for active case detection of visceral leishmaniasis in endemic districts of India, Nepal and Bangladesh, comparing yield, feasibility and costs. PLoS Negl Trop Dis (2011) 1.42

Challenges in HIV and visceral Leishmania co-infection: future research directions. Trop Med Int Health (2010) 1.41

Denied in Canada: why we need a global strategic plan for interventional radiology. J Vasc Interv Radiol (2008) 1.41

Antimonial treatment of visceral leishmaniasis: are current in vitro susceptibility assays adequate for prognosis of in vivo therapy outcome? Microbes Infect (2007) 1.40

Training, competency, and credentialing standards for diagnostic cervicocerebral angiography, carotid stenting, and cerebrovascular intervention: a joint statement from the American Academy of Neurology, American Association of Neurological Surgeons, American Society of Interventional and Therapeutic Radiology, American Society of Neuroradiology, Congress of Neurological Surgeons, AANS/CNS Cerebrovascular Section, and Society of Interventional Radiology. Radiology (2004) 1.40